Clinical Trials Logo

Clinical Trial Details — Status: Suspended

Administrative data

NCT number NCT03745859
Other study ID # 2018/302
Secondary ID
Status Suspended
Phase
First received
Last updated
Start date November 19, 2018
Est. completion date October 2023

Study information

Verified date December 2022
Source Norwegian University of Science and Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the feasibility of the Fraxinus Virtual Bronchoscope Navigation (VBN) System in the bronchoscopic access to target lesions. The study emphasizes the system´s efficacy in diagnostics of peripheral pulmonary lesions and the ease of use for the operator.


Description:

Multi-center study. The study explores Fraxinus which is an open source, software only, simple guiding system for bronchoscopy. The system provides 3D maps with centerline-to-target information extracted from preoperative computed tomography. The ability of the system to guide a user to a peripheral target lesion will be evaluated. During bronchoscopy any established method for diagnostic sampling is allowed. User Evaluation will be essential to decide if the Fraxinus VBN System is beneficial in a clinical setting.


Recruitment information / eligibility

Status Suspended
Enrollment 40
Est. completion date October 2023
Est. primary completion date October 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - referred to thoracic department in any of the participating hospitals with undiagnosed peripheral pulmonary lesion(s) not visible by bronchoscopy - voluntary signed an informed consent Exclusion Criteria: - pregnancy - Any patient that the Investigator feels is not appropriate for this study for any reason

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Fraxinus VBN system
Open source planning tool for bronchoscopy

Locations

Country Name City State
Norway St Olavs Hospital Trondheim

Sponsors (3)

Lead Sponsor Collaborator
Norwegian University of Science and Technology SINTEF Health Research, St. Olavs Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evidence if the Fraxinus VBN System has a role in the assessment of peripheral pulmonary lesions The proportion of cases in which the use of the system is considered beneficial 48 hours
Secondary Diagnostic yield Diagnostic success defined as cytology or biopsy with pathology 1 week
Secondary Duration of procedure Time spent with preparations and bronchoscopy 48 hours
Secondary Adverse events Procedure related adverse events or unexpected incidents registrated 48 hours
Secondary Operators-reported satisfaction Enquiry on main operator´s experience after end of bronchoscopy 48 hours
See also
  Status Clinical Trial Phase
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT02493023 - Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS N/A
Terminated NCT02050724 - ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT02804100 - Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients N/A
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Not yet recruiting NCT06376084 - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Recruiting NCT03402048 - The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial Phase 3
Recruiting NCT02264210 - Icotinib for Completed Resected IB NSCLC With EGFR Mutation Phase 2
Terminated NCT05153408 - (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC Phase 1
Completed NCT01261585 - Study of the Fixation of Various Vectors in PET/CT in Patients With a With Lung Cancer Before and During of CRT or RT N/A
Recruiting NCT06177925 - A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC Phase 2
Completed NCT02897778 - Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Phase 1
Completed NCT03516214 - EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations Phase 1
Completed NCT02745002 - Navigated EBUS and Functional Imaging in Lung Cancer N/A